Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $775.0 million
Deal Type : Collaboration
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis
Details : The collaboration of ProFound with Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $25.0 million
June 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $775.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Nosis, Daiichi Sankyo Partner for Cell-Targeted RNA Medicine Development
Details : The collaboration aims to leverage Nosis’ Connexa platform, to enable therapeutic access to extrahepatic cell types across multiple vital organs affected by chronic diseases.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Gensaic, Novo Nordisk Partner to Unlock Next-Gen Precision Therapies
Details : The collaboration unites Novo's deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology with the aim to treat cardiometabolic disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $354.0 million
March 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Perceptive Advisors
Deal Size : $300.0 million
Deal Type : Series A Financing
Kardigan Launches with Cozy $300M, Late-Stage Portfolio
Details : The funds from the financing will be used to advance Kardigan’s efforts in addressing the most critical unmet needs in cardiovascular diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Perceptive Advisors
Deal Size : $300.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $550.0 million
Deal Type : Collaboration
BioAge Partners with Novartis On Age-Related Disease Therapy Target Discovery
Details : The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms related to age-related diseases and conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $20.0 million
December 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $550.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $186 million
Deal Type : Collaboration
Photys and Novo Nordisk Partner to Develop Induced Proximity PHICS Technology
Details : The collaboration combines Novo’s deep expertise in cardiometabolic diseases with Photys’ PHICS technology to develop novel proximity-based therapeutics for a cardiometabolic disease target.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $186 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $1,460.0 million
Deal Type : Collaboration
Neomorph Announces Collaboration with Novo Nordisk to Discover Molecular Glue Degraders
Details : The collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $1,460.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $2,275.0 million
Deal Type : Collaboration
Details : The collaboration aims to focus on discovery, development and commercialization of up to five cardiovascular targets by leveraging Avidity's proprietary AOC platform technology, to deliver a new class of RNA therapeutics called Antibody Oligonucleotide C...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $100.0 million
November 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $2,275.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $2,760.0 million
Deal Type : Collaboration
Details : The collaboration will leverage Valo’s Opal Computational Platform including access to real-world patient data, AI-enabled small molecule discovery and Biowire® human tissue modelling platform to discover and develop novel treatments for cardiometabol...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $2,760.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Newpath Partners
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The financing will support Magnet's approach to the discovery and development of TrueGlues™, compounds inducing cooperative protein-protein interactions and will advance its portfolio spanning several indications, including oncology, cardiovascular, an...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Newpath Partners
Deal Size : $50.0 million
Deal Type : Series A Financing